Adult Burkitt's lymphoma

Clinical Lymphoma

Volumn 6, Issue 1, 2005, Pages 11-20

  Bociek, R Gregory ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

B cells; Central nervous system; Epstein Barr virus; HIV; Stem cell transplantation

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BUSULFAN; CD19 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN M; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LEUKOSIALIN; MESNA; METHEMOGLOBIN; METHOTREXATE; MYC PROTEIN; PREDNISONE; RASBURICASE; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINCRISTINE; BLEOMYCIN; RAPAMYCIN; RITUXIMAB; STEROID; URIC ACID;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW BIOPSY; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL STRUCTURE; CHROMOSOME TRANSLOCATION 8; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; FEVER; FLUID THERAPY; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; INTESTINE LYMPHOMA; LUMBAR PUNCTURE; LYMPHADENOPATHY; LYMPHOBLASTOMA; MEDICAL ASSESSMENT; MEDICAL LITERATURE; METHEMOGLOBINEMIA; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; ORGAN TRANSPLANTATION; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR LOCALIZATION; TUMOR LYSIS SYNDROME; VIRUS INFECTION; ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; BACTERIAL INFECTION; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM METASTASIS; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG MEGADOSE; GRAFT VERSUS LEUKEMIA EFFECT; HISTOPATHOLOGY; INTESTINE OBSTRUCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; NAUSEA; ONCOGENE C MYC; RASH; RESPIRATORY FAILURE; SURVIVAL RATE; UNDIFFERENTIATED LYMPHOMA; VIRUS CARCINOGENESIS; VIRUS LOAD; VOMITING;

EID: 22944453737     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.021     Document Type: Review

References (57)

1. Burkitt DP. A sarcoma involving the jaws in African children. Br J Surg 1958; 46:218-223.
2. Burkitt DP. Long-term remissions following one- and two-dose chemotherapy for African lymphoma. Cancer 1967; 20:756-759.
3. Burkitt DP, O'Conor GT. Malignant lymphoma in African children. Cancer 1961; 14:258-269.
4. O'Conor GT. Malignant lymphoma in African children II. A pathological entity. Cancer 1961; 14:270-283.
5. Hecht JL, Aster JC. Molecular Biology of Burkitt's Lymphoma. J Clin Oncol 2000; 18:3707-3721.
6. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001.
7. Grogan TM, Warnke RA, Kaplan HS. A comparative study of Burkitt's and non-Burkitt's "undifferentiated" malignant lymphoma: immunologic, cytochemical, ultrastructural, cytologic, histopathologic, clinical and cell culture features. Cancer 1982; 49:1817-1828.
8. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
9. The Non-Hodgkin's Lymphoma Classification Project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909-3918.
10. Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001; 97:3713-3720.
11. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002; 100:2950-2956.
12. Nakamura N, Nakamine H, Tamaru J, et al. The Distinction between Burkitt Lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol 2002; 15:771-776.
13. Slavutsky I, Andreoli G, Gutierrez M, et al. Variant (8;22) translocation in lymphoblastic lymphoma. Leuk Lymphoma 1996; 21:169-172.
14. Li Z, Van Calcar S, Qu C, et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003; 100:8164-8169.
15. McCarthy NJ, Hazlewood SA, Huen DS. The Epstein-Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl-2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. Adv Exp Med Biol 1996; 406:83-97.
16. Fanidi A, Hancock DC, Littlewood TD. Suppression of c-myc-induced apoptosis by the Epstein-Barr virus gene product BHRF1. J Virol 1998; 72:8392-8395.
17. Wilson JB, Levine AJ. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Cur Top Microbiol Immunol 1992; 182:375-384.
18. Baran-Marszak F, Fagard R, Girard B, et al. Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines. Lab Invest 2002; 82:1463-1479.
19. Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996; 14:2465-2472.
20. LaCasce AS, Howard OM, Li S, et al. The Magrath regimen is effective in older adults with Burkitt's and Burkitt-like lymphomas. Proc Am Soc Clin Oncol 2002; 21:288a (Absract #1150).
21. Economopoulos T, Dimopoulos MA, Foudoulakis A, et al. Burkitt's lymphoma in Greek adults. A study of the Hellenic co-operative oncology group. Leuk Res 2000; 24:993-998.
22. Levine PH, Kamaraju LS, Connelly RR, et al. The American Burkitt's Lymphoma Registry: eight years' experience. Cancer 1982; 49:1016-1022.
23. Sweetenham JW, Proctor SJ, Blaise D, et al. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience [published in erratum in Ann Oncol 1994; 5:545]. Ann Oncol 1994; 5(suppl 2):155-159.
24. Monabati A, Rakei SM, Kumar P, et al. Primary Burkitt lymphoma of the brain in an immunocompetent patient. Case report. J Neurosurg 2002; 96:1127-1129.
25. Gholam D, Bibeau F, El Weshi A, et al. Primary breast lymphoma. Leuk Lymphoma 2003; 44:1173-1178.
26. Blanc S, Bertrand Y, Lorthois-Ninou S, et al. Rectal localization of Burkitt's lymphoma. Arch Pediatr 2002; 9:1056-1058.
27. Bissen L, Brasseur R, Azagra JS, et al. Burkitt's lymphoma of the appendix. JBR-BTR 2002; 85:257-259.
28. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21:4402-4406.
29. Wossman W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of orate oxidase. Ann Hematol 2003; 82:160-165.
30. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97:2998-3003.
31. McGrath IT, Lee YJ, Anderson T, et al. Prognostic factors in Burkitt's lymphoma. importance of total tumor burden. Cancer 1980; 45:1507-1515.
32. Bernstein JI, Coleman CN, Strickler JG, et al. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's type). J Clin Oncol 1986; 4:847-858.
33. McGrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63:1102-1111.
34. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13:1264-1274.
35. Short-term intensive therapy for childhood non-Hodgkin's lymphoma. Lancet 1987; 1:1410-1412.
36. Kaiser U, Uebelacker I, Havemann K. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients. Leuk Lympboma 1999; 36:101-108.
37. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
38. Cohen Y, Amir G, Rachmilewitz EA, et al. Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma. Haematologica 2002; 87:ELT04.
39. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85:664-674.
40. McGrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphorna have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14:925-934.
41. Grigg AP, Seymour JF. Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma 2002; 43:889-892.
42. Ungkanont A, Mongkonsritrakoon W, Jootar S, Srichaikul T. Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplant 2000; 26:1351-1354.
43. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry roatched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31:667-678.
44. Straus DJ. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed Pharmacother 1996; 50:447-450.
45. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin's lymphoma. Lancet 1991; 337:805-809.
46. Spina M, Tirelli U, Zagonel V, et al. Burkitt's lymphoma in adults with and without human immunodefiency virus infection: a single institution clinicopathologic study of 75 patients. Cancer 1998; 82:766-774.
47. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999; 319:23-24.
48. Jones JL, Hanson DL, Dworkin MS, et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr 1999; 21 (suppl 1):S11-S17.
49. Ammassari A, Cingolani A, and Pezzotti P. AIDS-related central nervous system lymphoma: Changes of epidemiological trend and diagnostic attitudes in the era of HAART. J Acquir Immune Defic Syndr 1999; 21 (suppl):A34 (Abstract # 99).
50. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly-active antiretroviral therpay for patients with acquired immune deficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492-1499.
51. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98:1196-1205.
52. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514-1516.
53. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208-2216.
54. Pasquale MA, Weppler D, Smith J, et al. Burkitt's lymphoma variant of post-transplant lymphoproliferative disease (PTLD). Pathol Oncol Res 2002; 8:105-108.
55. Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol 2003; 27:818-827.
56. Xicoy B, Ribera JM, Esteve J, et al. Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHMA ALL-3/97 trial). Leuk Lymphoma 2003; 44:1541-1543.
57. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346:235-242.